MX2019012878A - Terapias para el tratamiento de enfermedades asociadas con la toxicidad del aldehido. - Google Patents
Terapias para el tratamiento de enfermedades asociadas con la toxicidad del aldehido.Info
- Publication number
- MX2019012878A MX2019012878A MX2019012878A MX2019012878A MX2019012878A MX 2019012878 A MX2019012878 A MX 2019012878A MX 2019012878 A MX2019012878 A MX 2019012878A MX 2019012878 A MX2019012878 A MX 2019012878A MX 2019012878 A MX2019012878 A MX 2019012878A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- related diseases
- toxic aldehyde
- aldehyde related
- toxic
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 2
- 231100000331 toxic Toxicity 0.000 title abstract 2
- 230000002588 toxic effect Effects 0.000 title abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 208000022873 Ocular disease Diseases 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000000266 injurious effect Effects 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 230000008506 pathogenesis Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 125000002924 primary amino group Chemical class [H]N([H])* 0.000 abstract 1
- 208000017520 skin disease Diseases 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/41—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K5/00—Use of organic ingredients
- C08K5/04—Oxygen-containing compounds
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K5/00—Use of organic ingredients
- C08K5/04—Oxygen-containing compounds
- C08K5/07—Aldehydes; Ketones
- C08K5/08—Quinones
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K5/00—Use of organic ingredients
- C08K5/16—Nitrogen-containing compounds
- C08K5/17—Amines; Quaternary ammonium compounds
- C08K5/18—Amines; Quaternary ammonium compounds with aromatically bound amino groups
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Polymers & Plastics (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
Abstract
La presente invención proporciona tratamiento, prevención, y/o reducción de un riesgo de una enfermedad, trastorno o condición en los cuales la toxicidad del aldehído está implicada en la patogénesis, incluyendo trastornos oculares, trastornos de la piel, condiciones asociadas con efectos dañinos de agentes vesicantes, y enfermedades autoinmune, inflamatoria, neurológica y cardiovascular con el uso de aminas primarias para atrapar aldehídos tóxicos, tales como MDA y HNE.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361755613P | 2013-01-23 | 2013-01-23 | |
US201361901796P | 2013-11-08 | 2013-11-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019012878A true MX2019012878A (es) | 2020-01-14 |
Family
ID=51228191
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015009383A MX2015009383A (es) | 2013-01-23 | 2014-01-23 | Enfermedades relacionadas con aldehido toxico y tratamiento. |
MX2019012878A MX2019012878A (es) | 2013-01-23 | 2015-07-21 | Terapias para el tratamiento de enfermedades asociadas con la toxicidad del aldehido. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015009383A MX2015009383A (es) | 2013-01-23 | 2014-01-23 | Enfermedades relacionadas con aldehido toxico y tratamiento. |
Country Status (13)
Country | Link |
---|---|
US (7) | US9687481B2 (es) |
EP (1) | EP2948149A4 (es) |
JP (5) | JP6514114B2 (es) |
KR (2) | KR102243169B1 (es) |
CN (3) | CN111135171B (es) |
AU (2) | AU2014209387B2 (es) |
CA (2) | CA3195807A1 (es) |
HK (1) | HK1217439A1 (es) |
IL (1) | IL239735B (es) |
MX (2) | MX2015009383A (es) |
RU (2) | RU2676694C9 (es) |
SG (1) | SG11201505587YA (es) |
WO (1) | WO2014116836A2 (es) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1888548B1 (en) | 2005-05-26 | 2012-08-22 | Neuron Systems, Inc | Quinoline derivative for the treatment of retinal diseases |
US9814701B2 (en) | 2009-12-11 | 2017-11-14 | Aldeyra Therapeutics, Inc. | Compositions and methods for the treatment of macular degeneration |
KR20150118106A (ko) | 2012-12-20 | 2015-10-21 | 알데이라 테라퓨틱스, 아이엔씨. | 페리-카르비놀 |
RU2676694C9 (ru) | 2013-01-23 | 2019-06-25 | Альдейра Терапьютикс, Инк. | Заболевания, связанные с токсичным альдегидом, и их лечение |
EP2948436A4 (en) * | 2013-01-25 | 2016-07-13 | Aldeyra Therapeutics Inc | NOVEL CASES IN THE TREATMENT OF MACULAR GENERATION |
CN107001267A (zh) * | 2014-08-08 | 2017-08-01 | 马合伙人株式会社 | 稠合杂环化合物 |
JP6947406B2 (ja) * | 2015-08-21 | 2021-10-13 | アルデイラ セラピューティクス, インコーポレイテッド | 重水素化化合物およびその使用 |
JP6959650B2 (ja) * | 2015-08-21 | 2021-11-02 | アルデイラ セラピューティクス, インコーポレイテッド | アルデヒドコンジュゲートおよびその使用 |
CN105085427B (zh) * | 2015-08-21 | 2018-06-05 | 中国科学院广州生物医药与健康研究院 | 一类苯并[d]异恶唑类化合物及其应用 |
CN116531400A (zh) | 2016-02-28 | 2023-08-04 | 奥尔德拉医疗公司 | 用环糊精治疗过敏性眼部病状 |
AU2017264697A1 (en) * | 2016-05-09 | 2018-11-22 | Aldeyra Therapeutics, Inc. | Combination treatment of ocular inflammatory disorders and diseases |
EP3500256A4 (en) * | 2016-08-22 | 2020-01-08 | Aldeyra Therapeutics, Inc. | ALDEHYDE CAPTURE CONNECTIONS AND USES THEREOF |
EP3596040B1 (en) * | 2017-03-16 | 2023-10-11 | Aldeyra Therapeutics, Inc. | Polymorphic salt of 6-chloro-3-amino-2(2-hydroxypropyl)quinoline and uses thereof |
MX2020003425A (es) | 2017-10-10 | 2020-07-29 | Aldeyra Therapeutics Inc | Tratamiento de trastornos inflamatorios. |
TWI685338B (zh) | 2017-12-14 | 2020-02-21 | 柯瑞 伊里阿斯 J | 使用非可吸收性口服投予之化合物之包括第2型糖尿病、脂肪肝炎及相關病況之人類代謝症候群之預防及治療 |
US20200038392A1 (en) | 2018-08-03 | 2020-02-06 | Aldeyra Therapeutics, Inc. | Topical compositions and methods of preparation and use |
JP2021533154A (ja) | 2018-08-06 | 2021-12-02 | アルデイラ セラピューティクス, インコーポレイテッド | 多形化合物およびその使用 |
WO2020068986A1 (en) | 2018-09-25 | 2020-04-02 | Aldeyra Therapeutics, Inc. | Formulations for treatment of dry eye disease |
WO2020198064A1 (en) | 2019-03-26 | 2020-10-01 | Aldeyra Therapeutics, Inc. | Ophthalmic formulations and uses thereof |
WO2020223685A1 (en) | 2019-05-02 | 2020-11-05 | Aldeyra Therapeutics, Inc. | Polymorphic compounds and uses thereof |
EP3785694A1 (en) * | 2019-08-30 | 2021-03-03 | Hangzhou Ocean Pearl Industrial Co., Ltd. | Eyeliner product and method thereof |
KR20220122978A (ko) * | 2019-12-30 | 2022-09-05 | 더 내셔널 인스티튜츠 오브 파마슈티컬 알앤디 컴퍼니 리미티드 | 삼환식 화합물, 및 그의 제조 방법 및 그의 의학적 용도 |
WO2021211625A1 (en) * | 2020-04-13 | 2021-10-21 | Aldeyra Therapeutics, Inc. | Quinoline compounds for treating lung, liver, and kidney diseases, disorders, or conditions |
JP7488166B2 (ja) | 2020-09-25 | 2024-05-21 | Jswアフティ株式会社 | ターゲットおよび成膜装置 |
US20240092744A1 (en) * | 2020-12-29 | 2024-03-21 | The National Institutes of Pharmaceutical R&D Co., Ltd. | Tricyclic compound, and preparation method therefor and medical use thereof |
CN115843293A (zh) * | 2021-06-25 | 2023-03-24 | 中国医药研究开发中心有限公司 | 三环化合物及其制备方法和医药用途 |
CN117580569A (zh) * | 2021-07-02 | 2024-02-20 | 奥尔德拉医疗公司 | 杂环型醛捕获化合物和其用途 |
Family Cites Families (122)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1020234A (en) | 1911-12-27 | 1912-03-12 | Charles Ward | Water-tube boiler. |
US2086186A (en) | 1933-10-10 | 1937-07-06 | Us Rubber Co | Treatment of rubber |
SU50906A1 (ru) | 1935-12-20 | 1936-11-30 | А.И. Бурляев | Веретено дл пр дильных машин |
GB1435721A (en) | 1972-05-18 | 1976-05-12 | Lilly Industries Ltd | Benzoxazole derivatives |
SU509046A1 (ru) | 1975-02-21 | 1984-06-23 | Всесоюзный научно-исследовательский химико-фармацевтический институт им.Серго Орджоникидзе | Производные 2-карбэтокси-3-аминоиндола,про вл ющие противовоспалительную активность, и способ их получени |
JPS6192592A (ja) | 1984-10-12 | 1986-05-10 | Norin Suisansyo Shokuhin Sogo Kenkyusho | 分岐サイクロデキストリンの製造方法 |
US4675332A (en) | 1984-12-10 | 1987-06-23 | Warner-Lambert Company | Acidic tetrazolyl substituted indole compounds and their use as antiallergy agents |
GB8610981D0 (en) | 1986-05-06 | 1986-06-11 | Ici America Inc | Quinoline amides |
US5032392A (en) | 1986-09-04 | 1991-07-16 | Vision Pharmaceuticals | Aqueous ophthalmic solutions for the treatment of dryness and/or irritation of human or animal eyes |
NZ225045A (en) | 1987-07-01 | 1990-06-26 | Janssen Pharmaceutica Nv | Antiviral pharmaceutical compositions containing cyclodextrin and an antiviral agent |
US5002935A (en) | 1987-12-30 | 1991-03-26 | University Of Florida | Improvements in redox systems for brain-targeted drug delivery |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
CA2072001C (en) | 1990-10-22 | 1998-11-03 | Nimai C. De | Method and composition for cleaning contact lenses |
CA2054339C (en) | 1990-11-02 | 2002-12-24 | Francesco G. Salituro | 3-amidoindolyl derivatives |
US5668117A (en) | 1991-02-22 | 1997-09-16 | Shapiro; Howard K. | Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments |
US6444221B1 (en) | 1992-06-30 | 2002-09-03 | Howard K. Shapiro | Methods of treating chronic inflammatory diseases using carbonyl trapping agents |
US20050090553A1 (en) | 1992-06-30 | 2005-04-28 | Shapiro Howard K. | Compositions and method for treatment of chronic inflammatory diseases |
US5472954A (en) | 1992-07-14 | 1995-12-05 | Cyclops H.F. | Cyclodextrin complexation |
TW401300B (en) | 1992-12-25 | 2000-08-11 | Senju Pharma Co | Antiallergic composition for ophthalmic or nasal use |
US5493027A (en) | 1993-01-22 | 1996-02-20 | Board Of Regents, The University Of Texas System | Anticonvulsive agents and uses thereof |
US5767109A (en) | 1993-10-20 | 1998-06-16 | Sanchez; Robert A. | Complexing urushiols |
US5576311A (en) | 1994-11-30 | 1996-11-19 | Pharmos Corporation | Cyclodextrins as suspending agents for pharmaceutical suspensions |
JP3297969B2 (ja) | 1994-12-26 | 2002-07-02 | ライオン株式会社 | 点眼剤 |
US5597823A (en) | 1995-01-27 | 1997-01-28 | Abbott Laboratories | Tricyclic substituted hexahydrobenz [e]isoindole alpha-1 adrenergic antagonists |
JP3736916B2 (ja) | 1996-02-19 | 2006-01-18 | 株式会社サンコンタクトレンズ | 含水性ソフトコンタクトレンズの消毒用組成物とその用途 |
CA2261916A1 (en) | 1996-08-01 | 1998-02-12 | Dowelanco Llc | 4-substituted quinoline derivatives having fungicidal activity |
US5742954A (en) | 1996-11-22 | 1998-04-28 | Softub, Inc. | Electrically powered spa jet unit |
JP2001524115A (ja) | 1997-05-02 | 2001-11-27 | シェリング アクチェンゲゼルシャフト | 置換された複素環式化合物及び医薬におけるその使用 |
KR20010041811A (ko) | 1998-03-12 | 2001-05-25 | 온토젠 코포레이션 | 단백질 티로신 포스파타제의 조절제 |
US6498154B1 (en) | 1999-05-04 | 2002-12-24 | Wyeth | Cyclic regimens using quinazolinone and benzoxazine derivatives |
US6358948B1 (en) | 1999-05-04 | 2002-03-19 | American Home Products Corporation | Quinazolinone and benzoxazine derivatives as progesterone receptor modulators |
JP3568108B2 (ja) | 1999-07-28 | 2004-09-22 | 松下電器産業株式会社 | デジタル地図の位置情報伝達方法とそれを実施する装置 |
WO2001041757A1 (fr) | 1999-12-10 | 2001-06-14 | Senju Pharmaceutical Co., Ltd. | Composition pharmaceutique contenant de la cyclodextrine |
US6569879B2 (en) | 2000-02-18 | 2003-05-27 | Merck & Co., Inc. | Aryloxyacetic acids for diabetes and lipid disorders |
JP4748289B2 (ja) | 2000-06-23 | 2011-08-17 | ライオン株式会社 | 点眼剤、眼科用組成物及び吸着抑制方法 |
FR2827599A1 (fr) * | 2001-07-20 | 2003-01-24 | Neuro3D | Composes derives de quinoleine et quinoxaline,preparation et utilisations |
UA83620C2 (ru) | 2001-12-05 | 2008-08-11 | Уайт | Замещенные бензоксазолы и их аналоги как эстрогенные агенты |
US20060014786A1 (en) | 2002-05-17 | 2006-01-19 | Rajeev Raut | Opthalmic pharmaceutical compositions and methods for treating ocular inflammation |
CA2451267A1 (en) | 2002-12-13 | 2004-06-13 | Warner-Lambert Company Llc | Pharmaceutical uses for alpha2delta ligands |
US20040198828A1 (en) | 2003-01-17 | 2004-10-07 | Abelson Mark B. | Combinational use of long-acting and short-acting anti-histamines for ocular allergies |
AU2004222279B2 (en) | 2003-03-14 | 2010-01-21 | University Of Washington | Retinoid replacements and opsin agonists and methods for the use thereof |
WO2004091630A1 (ja) | 2003-04-18 | 2004-10-28 | Advanced Medicine Research Institute | 眼に適用する疾患治療剤 |
US20060111318A1 (en) | 2003-04-18 | 2006-05-25 | Advanced Medicine Research Institute | Agent for treating eye diseases |
US7297709B2 (en) | 2003-05-22 | 2007-11-20 | Abbott Laboratories | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors |
US20040235892A1 (en) | 2003-05-22 | 2004-11-25 | Yujia Dai | Indazole and benzisoxazole kinase inhibitors |
US7083803B2 (en) | 2003-09-19 | 2006-08-01 | Advanced Ocular Systems Limited | Ocular solutions |
JP2005132834A (ja) | 2003-10-09 | 2005-05-26 | Kyowa Hakko Kogyo Co Ltd | キノリン誘導体 |
ES2426288T3 (es) | 2003-10-15 | 2013-10-22 | Ube Industries, Ltd. | Novedoso derivado de imidazol |
RU2006118325A (ru) | 2003-10-27 | 2007-12-10 | Астеллас Фарма Инк. (Jp) | Производные пиразина и их фармацевтическое применение |
WO2005051328A2 (en) | 2003-11-20 | 2005-06-09 | Othera Pharmaceuticals, Inc. | Amelioration of macular degeneration and other ophthalmic diseases |
US20050197292A1 (en) | 2004-01-30 | 2005-09-08 | Glennda Smithson | Compositions and methods for treating T-cell mediated pathological conditions |
KR20060135819A (ko) | 2004-02-17 | 2006-12-29 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 황반변성을 포함하는 안과질환의 관리 |
US20050234018A1 (en) | 2004-04-15 | 2005-10-20 | Allergan, Inc. | Drug delivery to the back of the eye |
JP2006008568A (ja) | 2004-06-24 | 2006-01-12 | Cyclochem:Kk | IgE抗体抑制剤および食品 |
WO2006002473A1 (en) | 2004-07-02 | 2006-01-12 | Adelaide Research & Innovation Pty Ltd | Method of controlling damage mediated by alpha, beta-unsaturated aldehydes |
FR2875409B1 (fr) | 2004-09-17 | 2010-05-07 | Sanofi Aventis | Composition pharmaceutique comprenant une dispersion solide a matrice polymere comprenant une phase continue de polydextrose et une phase continue d'un polymere autre que du polydextrose |
US20070287716A1 (en) | 2004-10-28 | 2007-12-13 | Hu Essa H | Pyrimidine and Quinoline Potentiators of Metabotropic Glutamate Receptors |
JPWO2006077821A1 (ja) | 2005-01-19 | 2008-06-19 | 大日本住友製薬株式会社 | アルドステロン受容体調節剤としての芳香族スルホン化合物 |
TW200640443A (en) | 2005-02-23 | 2006-12-01 | Alcon Inc | Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors |
CN1830964B (zh) * | 2005-03-11 | 2011-06-15 | 中国科学院上海药物研究所 | 4-取代苯氨基-3-硝基喹啉类化合物及其制备方法和用途 |
EP1888548B1 (en) * | 2005-05-26 | 2012-08-22 | Neuron Systems, Inc | Quinoline derivative for the treatment of retinal diseases |
WO2007077783A1 (ja) | 2005-12-27 | 2007-07-12 | Lion Corporation | ソフトコンタクトレンズ用組成物及び吸着抑制方法 |
US20070297981A1 (en) | 2006-01-25 | 2007-12-27 | Ousler George W Iii | Formulations and methods for treating dry eye |
JP4466875B2 (ja) | 2006-04-05 | 2010-05-26 | ライオン株式会社 | ソフトコンタクトレンズ用点眼剤 |
NZ590271A (en) | 2006-04-14 | 2011-12-22 | Prana Biotechnology Ltd | 9-hydroxy-3-substituted-4H-pyrido[1,2-a]pyrimidin-4-ones and 9-hydroxy-3-substituted-4H-pyrido[1,2-a]pyrimidin-4-thiones |
JP5194218B2 (ja) | 2006-06-05 | 2013-05-08 | 株式会社メニコンネクト | 含水性コンタクトレンズの保存方法ならびに該保存方法により保存された含水性コンタクトレンズ |
EP2079699A1 (en) | 2006-07-25 | 2009-07-22 | Envivo Pharmaceuticals, Inc. | Quinoline derivatives |
MX2009002166A (es) | 2006-08-31 | 2009-03-12 | Eurand Inc | Sistema de distribucion de farmacos, que comprenden soluciones solidas de farmacos debilmente basicos. |
US8158609B1 (en) | 2006-11-02 | 2012-04-17 | Novartis Ag | Use of cyclodextrins as an active ingredient for treating dry AMD and solubilizing drusen |
US20090118503A1 (en) | 2007-06-20 | 2009-05-07 | Kevin Sprott | Faah inhibitors |
CA2701116C (en) * | 2007-10-05 | 2013-02-05 | Acucela Inc. | Alkoxy compounds for disease treatment |
CA2714530C (en) | 2008-02-11 | 2018-09-25 | University Of Washington | Methods for the treatment and prevention of age-related retinal dysfunction |
WO2010019606A1 (en) | 2008-08-12 | 2010-02-18 | Sirtris Pharmaceuticals, Inc. | Benzoxazoles, benzthiazoles and related analogs as sirtuin modulators |
US20100240624A1 (en) | 2009-03-17 | 2010-09-23 | Aciex Therapeutics, Inc. | Ophthalmic Formulations of Ketotifen and Methods of Use |
WO2010133672A1 (en) | 2009-05-20 | 2010-11-25 | Clanotech Ab | Derivatives of quinoline-3-carboxylic acid and their medical use |
US20110105450A1 (en) | 2009-06-05 | 2011-05-05 | Aciex Therapeutics, Inc. | Ophthalmic formulations of fluticasone and methods of use |
US20100331315A1 (en) | 2009-06-18 | 2010-12-30 | Mustapha Haddach | Rhodanines and related heterocycles as kinase inhibitors |
WO2011008202A1 (en) | 2009-07-15 | 2011-01-20 | Vanderbilt University | Isoketal scavengers and mitigation of disorders involving oxidative injury |
TWI492769B (zh) | 2009-09-23 | 2015-07-21 | Alcon Res Ltd | 可注射的水性眼用組成物及其使用之方法 |
EP2509596B1 (en) | 2009-12-08 | 2019-08-28 | Case Western Reserve University | Gamma aminoacids for treating ocular disorders |
US9814701B2 (en) | 2009-12-11 | 2017-11-14 | Aldeyra Therapeutics, Inc. | Compositions and methods for the treatment of macular degeneration |
WO2011078204A1 (ja) * | 2009-12-24 | 2011-06-30 | 浜理薬品工業株式会社 | 高脂血症の予防または治療剤、および抗疲労剤 |
US8575221B2 (en) | 2010-03-17 | 2013-11-05 | Concert Pharmaceuticals, Inc. | Derivatives of dimethylcurcumin |
BR112013017943A2 (pt) | 2011-01-12 | 2018-12-18 | Array Biopharma Inc | benzoazepinas substituídas como moduladores receptores do tipo toll |
US10463687B2 (en) | 2011-01-20 | 2019-11-05 | Cornell University | Treatments for retinal disorders |
EP2670439B1 (en) * | 2011-01-31 | 2019-03-13 | PVAC Medical Technologies Ltd. | Active principle for mitigating undesired medical conditions |
TWI544922B (zh) | 2011-05-19 | 2016-08-11 | 愛爾康研究有限公司 | 高濃度歐羅派特錠(olopatadine)眼用組成物 |
US20130190500A1 (en) | 2011-12-12 | 2013-07-25 | Neuron Systems, Inc. | Process to prepare 6-chloro-3-amino-2-(2-hydroxypropyl)-1-azanaphthalene |
US9067963B2 (en) | 2012-08-01 | 2015-06-30 | Lewis and Clark Pharmaceuticals, LLC | N-alkyl 2-(disubstituted)alkynyladenosine-5-uronamides as A2A agonists |
KR20150118106A (ko) | 2012-12-20 | 2015-10-21 | 알데이라 테라퓨틱스, 아이엔씨. | 페리-카르비놀 |
RU2676694C9 (ru) | 2013-01-23 | 2019-06-25 | Альдейра Терапьютикс, Инк. | Заболевания, связанные с токсичным альдегидом, и их лечение |
EP2948436A4 (en) | 2013-01-25 | 2016-07-13 | Aldeyra Therapeutics Inc | NOVEL CASES IN THE TREATMENT OF MACULAR GENERATION |
US9713330B1 (en) | 2013-03-15 | 2017-07-25 | Deuteria Agrochemicals, Llc | Deuterium-enriched aldehydes |
US20160151410A1 (en) | 2013-07-02 | 2016-06-02 | The Trustees Of Columbia University In The City Of New York | Clearance of bioactive lipids from membrane structures by cyclodextrins |
EP3151818A4 (en) | 2014-06-04 | 2018-05-30 | Case Western Reserve University | Compositions and methods of treating diabetic retinopathy |
NO2721710T3 (es) | 2014-08-21 | 2018-03-31 | ||
MX2017002750A (es) | 2014-09-02 | 2017-08-02 | Singh Bhupinder | Metodo para marcar una molecula deuterada o no deuterada y formulaciones farmaceuticas para tratamiento. |
TW201628622A (zh) | 2014-11-17 | 2016-08-16 | 製藥公司 | Tlr抑制劑與布魯頓氏(bruton's)酪胺酸激酶抑制劑之組合 |
WO2016085939A2 (en) | 2014-11-24 | 2016-06-02 | Case Western Reserve University | Compounds and methods of treating ocular disorders |
JP6959650B2 (ja) | 2015-08-21 | 2021-11-02 | アルデイラ セラピューティクス, インコーポレイテッド | アルデヒドコンジュゲートおよびその使用 |
JP6947406B2 (ja) | 2015-08-21 | 2021-10-13 | アルデイラ セラピューティクス, インコーポレイテッド | 重水素化化合物およびその使用 |
CN116531400A (zh) | 2016-02-28 | 2023-08-04 | 奥尔德拉医疗公司 | 用环糊精治疗过敏性眼部病状 |
AU2017264697A1 (en) | 2016-05-09 | 2018-11-22 | Aldeyra Therapeutics, Inc. | Combination treatment of ocular inflammatory disorders and diseases |
KR102442964B1 (ko) | 2016-08-09 | 2022-09-14 | 코베스트로 도이칠란트 아게 | 실란-관능성 중합체성 폴리우레탄 |
WO2018039197A1 (en) | 2016-08-22 | 2018-03-01 | Aldeyra Therapeutics, Inc. | Aldehyde trapping compounds and methods of use thereof |
EP3500256A4 (en) | 2016-08-22 | 2020-01-08 | Aldeyra Therapeutics, Inc. | ALDEHYDE CAPTURE CONNECTIONS AND USES THEREOF |
BR112019006160A2 (pt) | 2016-09-28 | 2019-06-18 | Medicon Pharmaceuticals Inc | composições e métodos para o tratamento das condições oftálmicas |
EP3596040B1 (en) | 2017-03-16 | 2023-10-11 | Aldeyra Therapeutics, Inc. | Polymorphic salt of 6-chloro-3-amino-2(2-hydroxypropyl)quinoline and uses thereof |
MX2020003425A (es) | 2017-10-10 | 2020-07-29 | Aldeyra Therapeutics Inc | Tratamiento de trastornos inflamatorios. |
WO2020018498A1 (en) | 2018-07-16 | 2020-01-23 | Aldeyra Therapeutics, Inc. | Cyclodextrin formulations |
US20200038392A1 (en) | 2018-08-03 | 2020-02-06 | Aldeyra Therapeutics, Inc. | Topical compositions and methods of preparation and use |
JP2021533154A (ja) | 2018-08-06 | 2021-12-02 | アルデイラ セラピューティクス, インコーポレイテッド | 多形化合物およびその使用 |
WO2020068986A1 (en) | 2018-09-25 | 2020-04-02 | Aldeyra Therapeutics, Inc. | Formulations for treatment of dry eye disease |
US20210317385A1 (en) | 2018-10-02 | 2021-10-14 | Aldeyra Therapeutics, Inc. | Contact lens solutions and kits |
WO2020118045A1 (en) | 2018-12-05 | 2020-06-11 | Aldeyra Therapeutics, Inc. | Injectable formulations |
WO2020198064A1 (en) | 2019-03-26 | 2020-10-01 | Aldeyra Therapeutics, Inc. | Ophthalmic formulations and uses thereof |
US20220089542A1 (en) | 2019-05-02 | 2022-03-24 | Aldeyra Therapeutics, Inc. | Process for preparation of aldehyde scavenger and intermediates |
WO2020223685A1 (en) | 2019-05-02 | 2020-11-05 | Aldeyra Therapeutics, Inc. | Polymorphic compounds and uses thereof |
US20230131929A1 (en) | 2020-03-24 | 2023-04-27 | Aldeyra Therapeutics, Inc. | Quinoline compounds for treating respiratory disorders and viral infections |
WO2021211625A1 (en) | 2020-04-13 | 2021-10-21 | Aldeyra Therapeutics, Inc. | Quinoline compounds for treating lung, liver, and kidney diseases, disorders, or conditions |
EP4149470A4 (en) | 2020-05-13 | 2024-04-24 | Aldeyra Therapeutics Inc | PHARMACEUTICAL FORMULATIONS AND USES THEREOF |
JP2023529840A (ja) | 2020-06-04 | 2023-07-12 | アルデイラ セラピューティクス, インコーポレイテッド | ドライアイ疾患バイオマーカーおよび処置するための該バイオマーカーの使用 |
-
2014
- 2014-01-23 RU RU2015126016A patent/RU2676694C9/ru active
- 2014-01-23 CN CN202010058756.7A patent/CN111135171B/zh active Active
- 2014-01-23 MX MX2015009383A patent/MX2015009383A/es unknown
- 2014-01-23 AU AU2014209387A patent/AU2014209387B2/en active Active
- 2014-01-23 SG SG11201505587YA patent/SG11201505587YA/en unknown
- 2014-01-23 KR KR1020157022673A patent/KR102243169B1/ko active IP Right Grant
- 2014-01-23 CA CA3195807A patent/CA3195807A1/en active Pending
- 2014-01-23 CA CA2898631A patent/CA2898631C/en active Active
- 2014-01-23 CN CN202311132218.8A patent/CN117045653A/zh active Pending
- 2014-01-23 JP JP2015553925A patent/JP6514114B2/ja active Active
- 2014-01-23 WO PCT/US2014/012762 patent/WO2014116836A2/en active Application Filing
- 2014-01-23 EP EP14743711.5A patent/EP2948149A4/en active Pending
- 2014-01-23 US US14/760,039 patent/US9687481B2/en active Active
- 2014-01-23 KR KR1020217011262A patent/KR102435676B1/ko active IP Right Grant
- 2014-01-23 RU RU2018145691A patent/RU2018145691A/ru not_active Application Discontinuation
- 2014-01-23 CN CN201480005853.2A patent/CN105120866B/zh active Active
-
2015
- 2015-07-01 IL IL239735A patent/IL239735B/en active IP Right Grant
- 2015-07-21 MX MX2019012878A patent/MX2019012878A/es unknown
-
2016
- 2016-05-12 HK HK16105462.0A patent/HK1217439A1/zh unknown
-
2017
- 2017-05-09 US US15/590,708 patent/US10213395B2/en active Active
-
2018
- 2018-10-05 AU AU2018241154A patent/AU2018241154A1/en not_active Abandoned
- 2018-10-22 JP JP2018198154A patent/JP7221021B2/ja active Active
-
2019
- 2019-01-30 US US16/262,364 patent/US10543181B2/en active Active
- 2019-02-15 US US16/277,865 patent/US10588874B2/en active Active
-
2020
- 2020-01-27 US US16/773,654 patent/US11007157B2/en active Active
- 2020-02-25 JP JP2020029608A patent/JP2020079305A/ja not_active Withdrawn
-
2021
- 2021-04-12 US US17/227,568 patent/US11701331B2/en active Active
-
2022
- 2022-03-07 US US17/653,827 patent/US11771664B2/en active Active
- 2022-09-22 JP JP2022151228A patent/JP7457401B2/ja active Active
-
2024
- 2024-03-08 JP JP2024036019A patent/JP2024057103A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019012878A (es) | Terapias para el tratamiento de enfermedades asociadas con la toxicidad del aldehido. | |
MX2018002157A (es) | Conjugados de aldehido y usos de los mismos. | |
MX2019001722A (es) | Compuestos de captura de aldehido y usos de los mismos. | |
MX2018002155A (es) | Compuestos deuterados y usos de los mismos. | |
PH12018500041A1 (en) | Substituted aza compoounds as irak-4 inhibitors | |
PH12018500040A1 (en) | Indazole and azaindazole compounds as irak-4 inhibitors | |
BR112018000691A2 (pt) | inibidores peptídicos do receptor de interleucina-23 e seu uso para tratar doenças inflamatórias | |
PH12016502382A1 (en) | Substituted indazole compounds as irak4 inhibitors | |
NZ720949A (en) | Methods and compositions for treating aging-associated conditions | |
MX2019000965A (es) | Composiciones y metodos para inihibir la masp-3 para el tratamiento de diferentes enfermedades y trastornos. | |
PH12016501702B1 (en) | Pyrazole amide derivative | |
EA201600589A1 (ru) | Ингибиторы диацилглицеринацилтрансферазы 2 для применения в лечении метаболических и связанных с метаболизмом расстройств | |
EA201391033A1 (ru) | Ингибиторы bace-2 для лечения метаболических расстройств | |
PH12015501697A1 (en) | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity | |
EA201201201A1 (ru) | Новые ингибиторы rock | |
EA201792604A1 (ru) | Ингибиторы аутотаксина и их применения | |
MX360888B (es) | Formulaciones oculares para suministro de fármaco al segmento posterior del ojo. | |
EA201991387A1 (ru) | ТРИЦИКЛИЧЕСКИЕ ЕНОНЫ - ПРОИЗВОДНЫЕ ПИРИМИДИНА ДЛЯ ИНГИБИРОВАНИЯ ROR-γ И ДРУГИХ ПРИМЕНЕНИЙ | |
EA202091020A1 (ru) | Замещенные имидазопиридинамиды и их применение | |
EA201792610A1 (ru) | Способ лечения неврологического заболевания | |
MX2019006863A (es) | Inhibidores de heparanasa y uso de los mismos. | |
UA118130C2 (uk) | Заміщені біциклічні дигідропіримідинони і їх застосування як інгібіторів активності нейтрофіл-еластази | |
MX2017003016A (es) | Derivados de piridazinona como inhibidores de las fosfoinositido-3-cinasas. | |
MX2018006631A (es) | Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas. | |
MX2016015767A (es) | Compuestos para el tratamiento de convulsiones y otros trastornos y condiciones del sistema nervioso central. |